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The letter from Drs Bhargava and Dabbs [1] expressed
concern with the immunohistochemical (IHC) criteria we used
to define breast cancer molecular phenotypes in our study
[2]. Although expression arrays are the ‘gold standard’ for
defining these subtypes, there is sufficient evidence to
suggest that the markers we selected provide a reasonable
approximation of molecular phenotypes, as determined by
gene expression profiling. For a large study such as ours, in
which we collected more than 2,800 formalin-fixed, paraffin-
embedded tissue samples from cancers occurring over a
20-year period, logistical and technical issues precluded the
feasibility of our conducting expression array analyses. The
obvious limitation of using IHC markers to define subtypes is
that this may result in the misclassification of some tumors.
The criteria for defining molecular subtypes according to IHC
markers are not standardized. In general, it is accepted that
relative to luminal A cancers, luminal B tumors have lower
expression levels of estrogen receptor (ER)/progesterone
receptor (PR) and related genes, higher proliferative rates,
and are of higher grade. In addition, some tumors defined as
luminal B by expression array are human epidermal growth
factor receptor (HER)2 positive [3]. However, how best to
combine various IHC markers to most closely approximate
tumor types as defined by expression profiling remains open
to debate. One suggested definition of luminal B cancers is
the one we used in our study (ER positive or PR positive and
HER2 positive). Other large population-based studies have
also utilized the same criteria (or other ER positive/HER2
positive criteria) to define luminal B tumors [4-6].
Despite the potential for misclassification of phenotypes
when using IHC, we and others [4,5] have demonstrated that
IHC marker defined phenotypes are associated with clinical
characteristics similar to those seen in studies using
expression array defined subtypes. In our preliminary
analyses, using the same subtype definitions, we found that
women with luminal B tumors have outcomes intermediate
between those with luminal A and other subtypes. These
findings are consistent with those in subtypes defined by
expression array analysis [3].
Drs Bhargava and Dabbs suggest the use of semiquantitative
IHC to define and distinguish luminal A and B subtypes [1].
We agree that utilizing a continuous measure of ER
maximizes the use of data and may be more biologically
informative. However, quantitative assessment of ER by IHC
is subject to error because it is highly influenced by variability
in pre-analytic, analytic, and post-analytic factors. Until
methodologic studies are conducted that address these
issues, it is unclear that our study would benefit from this type
of information.
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